##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 1 (2025)

Prevalence and incidence of sarcopenia in Swiss postmenopausal women: findings from the OsteoLaus Cohort

Cite this as:
Swiss Med Wkly. 2025;155:4034
Published
17.01.2025

Summary

STUDY AIMS: Sarcopenia is a progressive, age-related loss of muscle mass, strength and function. Given the ageing population and the adverse outcomes associated with sarcopenia, monitoring its epidemiology is particularly important. This study aimed to describe sarcopenia prevalence, 5-year incidence and agreement between definitions using the latest operational criteria in Swiss postmenopausal women.

METHODS: Postmenopausal women from the last 5 years of the CoLaus/OsteoLaus prospective population-based cohort were included based on complete case analysis (April 2015 to October 2022; Lausanne, Switzerland). We assessed appendicular lean mass via Dual X-ray Absorptiometry (GE Lunar iDXA), handgrip strength using a Jamar Dynamometer and 6-metre gait speed at multiple visits. Sarcopenia was defined based on handgrip strength and/or appendicular lean mass and/or gait speed using 11 definitions, including that from the European Working Group on Sarcopenia in Older People (EWGSOPII, 2019). Prevalence was measured as the number and rate of sarcopenic cases at the last visit, while incidence was measured as the number and rate of new sarcopenic cases over 2.5 or 5 years.

RESULTS: A total of 930 women were included, with a mean (standard deviation) age of 72.9 (6.9) years, BMI of 25.7 (4.8) kg/m2, appendicular lean mass 16.8 (2.5) kg, handgrip strength 21.2 (5.5) kg, gait speed 1.1 (0.2) m/s. Sarcopenia prevalence based on EWGSOPII definitions ranged from 2.2% to 5.7%, while other definitions varied from 0.5% to 13.4%. The 5-year incidence rates based on EWGSOPII were 1.9% to 4.7%. Prevalence and incidence increased significantly between the lowest and highest age tertiles (Fisher’s exact test, p <0.05) for most definitions. Agreement between definitions was predominantly “none” or “minimal” according to the Cohen Kappa score.

CONCLUSION: This population-based cohort of postmenopausal women highlights an increase in sarcopenia prevalence and incidence beginning in the seventh decade of life, underscoring the accelerated decline in muscle health with age. The minimal agreement between the definitions highlights the need for a consensus, which would improve future research and clinical implementations.

References

  1. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998 Apr;147(8):755–63. 10.1093/oxfordjournals.aje.a009520
  2. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al.; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan;48(1):16–31. 10.1093/ageing/afy169
  3. B. Vellas, R.A. Fielding, C. Bens, R. Bernabei, P.M. Cawthon, T. Cederholm, et al. Implications of ICD-10 for sarcopenia clinical practice and clinical trials: report by the international conference on frailty and sarcopenia research task force 2017. https://doi.org/10.14283/JFA.2017.30. doi: https://doi.org/10.14283/jfa.2017.30
  4. Kirk B, Cawthon PM, Arai H, Ávila-Funes JA, Barazzoni R, Bhasin S, et al.; Global Leadership Initiative in Sarcopenia (GLIS) group. The Conceptual Definition of Sarcopenia: Delphi Consensus from the Global Leadership Initiative in Sarcopenia (GLIS). Age Ageing. 2024 Mar;53(3):afae052. 10.1093/ageing/afae052
  5. Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyère O. Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PLoS One. 2017 Jan;12(1):e0169548. 10.1371/journal.pone.0169548
  6. Cawthon PM, Manini T, Patel SM, Newman A, Travison T, Kiel DP, et al. Putative Cut-Points in Sarcopenia Components and Incident Adverse Health Outcomes: an SDOC Analysis. J Am Geriatr Soc. 2020 Jul;68(7):1429–37. 10.1111/jgs.16517
  7. Vendrami C, Shevroja E, Gonzalez Rodriguez E, Gatineau G, Elmers J, Reginster J, et al. Muscle parameters in fragility fracture risk prediction in older adults: A scoping review. J Cachexia Sarcopenia Muscle 2024:jcsm.13418. https://doi.org/10.1002/jcsm.13418.
  8. Yuan S, Larsson SC. Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. Metabolism. 2023 Jul;144:155533. 10.1016/j.metabol.2023.155533
  9. Beaudart C, Dawson A, Shaw SC, Harvey NC, Kanis JA, Binkley N, et al.; IOF-ESCEO Sarcopenia Working Group. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos Int. 2017 Jun;28(6):1817–33. 10.1007/s00198-017-3980-9
  10. Pinedo-Villanueva R, Westbury LD, Syddall HE, Sanchez-Santos MT, Dennison EM, Robinson SM, et al. Health Care Costs Associated With Muscle Weakness: A UK Population-Based Estimate. Calcif Tissue Int. 2019 Feb;104(2):137–44. 10.1007/s00223-018-0478-1
  11. OECD. OECD Economic Surveys: Switzerland 2019. OECD; 2019. https://doi.org/10.1787/7e6fd372-en.
  12. Mayhew AJ, Amog K, Phillips S, Parise G, McNicholas PD, de Souza RJ, et al. The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: a systematic review and meta-analyses. Age Ageing. 2019 Jan;48(1):48–56. 10.1093/ageing/afy106
  13. Stuck AK, Tsai LT, Freystaetter G, Vellas B, Kanis JA, Rizzoli R, et al. Comparing Prevalence of Sarcopenia Using Twelve Sarcopenia Definitions in a Large Multinational European Population of Community-Dwelling Older Adults. J Nutr Health Aging. 2023;27(3):205–12. 10.1007/s12603-023-1888-y
  14. Bertschi D, Kiss CM, Beerli N, Kressig RW. Sarcopenia in hospitalized geriatric patients: insights into prevalence and associated parameters using new EWGSOP2 guidelines. Eur J Clin Nutr. 2021 Apr;75(4):653–60. 10.1038/s41430-020-00780-7
  15. Wearing J, Konings P, de Bie RA, Stokes M, de Bruin ED. Prevalence of probable sarcopenia in community-dwelling older Swiss people - a cross-sectional study. BMC Geriatr. 2020 Aug;20(1):307. 10.1186/s12877-020-01718-1
  16. Hars M, Biver E, Chevalley T, Herrmann F, Rizzoli R, Ferrari S, et al. Low Lean Mass Predicts Incident Fractures Independently From FRAX: a Prospective Cohort Study of Recent Retirees. J Bone Miner Res. 2016 Nov;31(11):2048–56. 10.1002/jbmr.2878
  17. Graf CE, Pichard C, Herrmann FR, Sieber CC, Zekry D, Genton L. Prevalence of low muscle mass according to body mass index in older adults. Nutrition. 2017 Feb;34:124–9. 10.1016/j.nut.2016.10.002
  18. Stuck AK, Mäder NC, Bertschi D, Limacher A, Kressig RW. Performance of the EWGSOP2 Cut-Points of Low Grip Strength for Identifying Sarcopenia and Frailty Phenotype: A Cross-Sectional Study in Older Inpatients. Int J Environ Res Public Health. 2021 Mar;18(7):3498. 10.3390/ijerph18073498
  19. Firmann M, Mayor V, Vidal PM, Bochud M, Pécoud A, Hayoz D, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord. 2008 Mar;8(1):6. 10.1186/1471-2261-8-6
  20. Shevroja E, Marques-Vidal P, Aubry-Rozier B, Hans G, Rivadeneira F, Lamy O, et al. Cohort profile: the OsteoLaus study. Int J Epidemiol. 2019 Aug;48(4):1046–1047g. 10.1093/ije/dyy276
  21. Therapists AS of H. MacDermid J, Solomon G, Valdes K. Clinical Assessment Recommendations. American Society of Hand Therapists; 2015.
  22. Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, et al. Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. J Clin Densitom. 2019;22(4):453–71. 10.1016/j.jocd.2019.07.001
  23. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020 Mar;21(3):300–307.e2. 10.1016/j.jamda.2019.12.012
  24. Shaffer NC, Ferrucci L, Shardell M, Simonsick EM, Studenski S. Agreement and Predictive Validity Using Less Conservative FNIH Sarcopenia Project Weakness Cutpoints. J Am Geriatr Soc. 2017;65:574–9. 10.1111/jgs.14706
  25. Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014 May;69(5):547–58. 10.1093/gerona/glu010
  26. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al.; International Working Group on Sarcopenia. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011 May;12(4):249–56. 10.1016/j.jamda.2011.01.003
  27. Daly RM, Iuliano S, Fyfe JJ, Scott D, Kirk B, Thompson MQ, et al. Screening, Diagnosis and Management of Sarcopenia and Frailty in Hospitalized Older Adults: Recommendations from the Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) Expert Working Group. J Nutr Health Aging. 2022;26(6):637–51. 10.1007/s12603-022-1801-0
  28. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276–82. doi: https://doi.org/10.11613/BM.2012.031
  29. Healthcare - Pocket Statistics. 2024. Neuchâtel: Bundesamt für Statistik (BFS); 2024.
  30. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006 Oct;61(10):1059–64. 10.1093/gerona/61.10.1059
  31. Kim KM, Lim S, Oh TJ, Moon JH, Choi SH, Lim JY, et al. Longitudinal Changes in Muscle Mass and Strength, and Bone Mass in Older Adults: Gender-Specific Associations Between Muscle and Bone Losses. J Gerontol A Biol Sci Med Sci. 2018 Jul;73(8):1062–9. 10.1093/gerona/glx188
  32. Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol. 2012 Jul;3:260. 10.3389/fphys.2012.00260
  33. G. Faxén-Irving, Y. Luiking, H. Grönstedt, E. Franzén, Å. Seiger, S. Vikström, et al. Do malnutrition, sarcopenia and frailty overlap in nursing-home residents? 2020. https://doi.org/10.14283/JFA.2020.45. doi: https://doi.org/10.14283/jfa.2020.45
  34. Ida S, Imataka K, Morii S, Katsuki K, Murata K. Frequency and Overlap of Cachexia, Malnutrition, and Sarcopenia in Elderly Patients with Diabetes Mellitus: A Study Using AWGC, GLIM, and AWGS2019. Nutrients. 2024 Jan;16(2):236. 10.3390/nu16020236
  35. Cawthon PM, Visser M, Arai H, Ávila-Funes JA, Barazzoni R, Bhasin S, et al. Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee. Eur Geriatr Med. 2022 Dec;13(6):1239–44. 10.1007/s41999-022-00706-5
  36. Shen Y, Shi Q, Nong K, Li S, Yue J, Huang J, et al. Exercise for sarcopenia in older people: A systematic review and network meta-analysis. J Cachexia Sarcopenia Muscle. 2023 Jun;14(3):1199–211. 10.1002/jcsm.13225
  37. Nasimi N, Sohrabi Z, Nunes EA, Sadeghi E, Jamshidi S, Gholami Z, et al. Whey Protein Supplementation with or without Vitamin D on Sarcopenia-Related Measures: A Systematic Review and Meta-Analysis. Adv Nutr. 2023 Jul;14(4):762–73. 10.1016/j.advnut.2023.05.011
  38. Bahat G, Ozkok S. The Current Landscape of Pharmacotherapies for Sarcopenia. Drugs Aging. 2024 Feb;41(2):83–112. 10.1007/s40266-023-01093-7
  39. World Health Organization. Global action plan on physical activity 2018–2030: more active people for a healthier world. Geneva: World Health Organization; 2018.
  40. Office fédéral du sport OFSPO, Office fédéral de la santé publique OFSP, Promotion Santé Suisse, Bureau de prévention des accidents bpa, Réseau suisse Santé et activité physique hepa. Recommandations suisses en matière d’activité physique - Bases. Macolin: OFSPO; 2022.